Cited 10 times in
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김민환 | - |
dc.contributor.author | 김현기 | - |
dc.contributor.author | 김형일 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 박형순 | - |
dc.contributor.author | 범승훈 | - |
dc.contributor.author | 손태일 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 정인경 | - |
dc.contributor.author | 정재호 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 최윤영 | - |
dc.contributor.author | 형우진 | - |
dc.contributor.author | 장향란 | - |
dc.date.accessioned | 2019-09-20T07:43:42Z | - |
dc.date.available | 2019-09-20T07:43:42Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171034 | - |
dc.description.abstract | PURPOSE: Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection. Materials and Methods: This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values. RESULTS: Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis. CONCLUSION: This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | Cancer Research and Treatment | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | B7-H1 Antigen/metabolism | - |
dc.subject.MESH | Biomarkers, Tumor* | - |
dc.subject.MESH | Clinical Trials, Phase III as Topic | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | DNA-Binding Proteins/metabolism | - |
dc.subject.MESH | Endonucleases/metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multicenter Studies as Topic | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Randomized Controlled Trials as Topic | - |
dc.subject.MESH | Stomach Neoplasms/metabolism* | - |
dc.subject.MESH | Stomach Neoplasms/mortality* | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Stomach Neoplasms/therapy | - |
dc.title | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Min Hwan Kim | - |
dc.contributor.googleauthor | Xianglan Zhang | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Inkyung Jung | - |
dc.contributor.googleauthor | Hyung Soon Park | - |
dc.contributor.googleauthor | Seung-Hoon Beom | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Hyunki Kim | - |
dc.contributor.googleauthor | Yoon Young Choi | - |
dc.contributor.googleauthor | Taeil Son | - |
dc.contributor.googleauthor | Hyoung-Il Kim | - |
dc.contributor.googleauthor | Jae-Ho Cheong | - |
dc.contributor.googleauthor | Woo Jin Hyung | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.identifier.doi | 10.4143/crt.2018.331 | - |
dc.contributor.localId | A00482 | - |
dc.contributor.localId | A01108 | - |
dc.contributor.localId | A01154 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A04576 | - |
dc.contributor.localId | A04581 | - |
dc.contributor.localId | A01998 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A03693 | - |
dc.contributor.localId | A03717 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A04138 | - |
dc.contributor.localId | A04382 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 30282452 | - |
dc.subject.keyword | Biomarkers | - |
dc.subject.keyword | ERCC1 | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Stomach neoplasms | - |
dc.subject.keyword | Thymidylate synthase | - |
dc.contributor.alternativeName | Kim, Min Hwan | - |
dc.contributor.affiliatedAuthor | 김민환 | - |
dc.contributor.affiliatedAuthor | 김현기 | - |
dc.contributor.affiliatedAuthor | 김형일 | - |
dc.contributor.affiliatedAuthor | 김효송 | - |
dc.contributor.affiliatedAuthor | 노성훈 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 박형순 | - |
dc.contributor.affiliatedAuthor | 범승훈 | - |
dc.contributor.affiliatedAuthor | 손태일 | - |
dc.contributor.affiliatedAuthor | 정민규 | - |
dc.contributor.affiliatedAuthor | 정인경 | - |
dc.contributor.affiliatedAuthor | 정재호 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.contributor.affiliatedAuthor | 최윤영 | - |
dc.contributor.affiliatedAuthor | 형우진 | - |
dc.citation.volume | 51 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 819 | - |
dc.citation.endPage | 831 | - |
dc.identifier.bibliographicCitation | Cancer Research and Treatment, Vol.51(2) : 819-831, 2019 | - |
dc.identifier.rimsid | 64234 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.